Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer

NCT00039780 is registered in ClinicalTrials.gov with BioNumerik Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00039780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00039780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer
Lead sponsor
BioNumerik Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2001
Completion date
September 30, 2014
Enrollment
764 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast diseases, breast neoplasms, metastases, neoplasm